Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: Reassessing efficacy using endpoints from clinical trials.

Bernstein DI, Cardin RD, Pullum DA, Bravo FJ, Kousoulas KG, Dixon DA.

PLoS One. 2019 Mar 27;14(3):e0213401. doi: 10.1371/journal.pone.0213401. eCollection 2019.

2.

The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.

Bernstein DI, Pullum DA, Cardin RD, Bravo FJ, Dixon DA, Kousoulas KG.

Vaccine. 2019 Jan 3;37(1):61-68. doi: 10.1016/j.vaccine.2018.11.042. Epub 2018 Nov 22.

PMID:
30471955
3.

Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses.

Stanfield BA, Rider PJF, Caskey J, Del Piero F, Kousoulas KG.

Vaccine. 2018 May 11;36(20):2842-2849. doi: 10.1016/j.vaccine.2018.03.075. Epub 2018 Apr 11.

PMID:
29655629
4.
5.

Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.

Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, Straus SE, Cohen JI.

J Infect Dis. 2009 Oct 1;200(7):1088-95. doi: 10.1086/605645.

6.

Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4+ and CD8+ TRM Cells Associated with Protection against Recurrent Genital Herpes.

Srivastava R, Roy S, Coulon PG, Vahed H, Prakash S, Dhanushkodi N, Kim GJ, Fouladi MA, Campo J, Teng AA, Liang X, Schaefer H, BenMohamed L.

J Virol. 2019 Apr 17;93(9). pii: e02309-18. doi: 10.1128/JVI.02309-18. Print 2019 May 1.

PMID:
30787156
7.

A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.

Wang K, Goodman KN, Li DY, Raffeld M, Chavez M, Cohen JI.

J Virol. 2015 Nov 11;90(1):562-74. doi: 10.1128/JVI.01845-15. Print 2016 Jan 1.

8.

Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.

Awasthi S, Balliet JW, Flynn JA, Lubinski JM, Shaw CE, DiStefano DJ, Cai M, Brown M, Smith JF, Kowalski R, Swoyer R, Galli J, Copeland V, Rios S, Davidson RC, Salnikova M, Kingsley S, Bryan J, Casimiro DR, Friedman HM.

J Virol. 2014 Feb;88(4):2000-10. doi: 10.1128/JVI.03163-13. Epub 2013 Nov 27.

9.

Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig.

Bernstein DI, Earwood JD, Bravo FJ, Cohen GH, Eisenberg RJ, Clark JR, Fairman J, Cardin RD.

Vaccine. 2011 Mar 3;29(11):2071-8. doi: 10.1016/j.vaccine.2011.01.005. Epub 2011 Jan 14.

10.

Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.

Morello CS, Kraynyak KA, Levinson MS, Chen Z, Lee KF, Spector DH.

Vaccine. 2012 Oct 12;30(46):6541-6550. doi: 10.1016/j.vaccine.2012.08.049. Epub 2012 Sep 1.

11.

Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.

Bourne N, Bravo FJ, Francotte M, Bernstein DI, Myers MG, Slaoui M, Stanberry LR.

J Infect Dis. 2003 Feb 15;187(4):542-9. Epub 2003 Feb 7.

PMID:
12599070
12.

A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.

Stanfield BA, Stahl J, Chouljenko VN, Subramanian R, Charles AS, Saied AA, Walker JD, Kousoulas KG.

PLoS One. 2014 Oct 28;9(10):e109890. doi: 10.1371/journal.pone.0109890. eCollection 2014.

13.

Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus 1 Vaccine Strain VC2 Expressing Equine Herpesvirus 1 (EHV-1) Glycoprotein D Generates Anti-EHV-1 Immune Responses in Mice.

Liu SA, Stanfield BA, Chouljenko VN, Naidu S, Langohr I, Del Piero F, Ferracone J, Roy AA, Kousoulas KG.

J Virol. 2017 May 26;91(12). pii: e02445-16. doi: 10.1128/JVI.02445-16. Print 2017 Jun 15.

14.
15.

The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs.

Bernstein DI, Farley N, Bravo FJ, Earwood J, McNeal M, Fairman J, Cardin R.

Vaccine. 2010 May 7;28(21):3748-53. doi: 10.1016/j.vaccine.2009.10.025. Epub 2009 Oct 24.

16.

Vaccination of rhesus macaques with the live-attenuated HSV-1 vaccine VC2 stimulates the proliferation of mucosal T cells and germinal center responses resulting in sustained production of highly neutralizing antibodies.

Stanfield BA, Pahar B, Chouljenko VN, Veazey R, Kousoulas KG.

Vaccine. 2017 Jan 23;35(4):536-543. doi: 10.1016/j.vaccine.2016.12.018. Epub 2016 Dec 22.

17.

Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.

Çuburu N, Wang K, Goodman KN, Pang YY, Thompson CD, Lowy DR, Cohen JI, Schiller JT.

J Virol. 2015 Jan;89(1):83-96. doi: 10.1128/JVI.02380-14. Epub 2014 Oct 15.

18.

Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.

Awasthi S, Huang J, Shaw C, Friedman HM.

J Virol. 2014 Aug;88(15):8421-32. doi: 10.1128/JVI.01130-14. Epub 2014 May 14.

20.

Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.

Hook LM, Cairns TM, Awasthi S, Brooks BD, Ditto NT, Eisenberg RJ, Cohen GH, Friedman HM.

PLoS Pathog. 2018 May 23;14(5):e1007095. doi: 10.1371/journal.ppat.1007095. eCollection 2018 May.

Supplemental Content

Support Center